Beijing Continent Pharmaceutical Co, Ltd.

This study tests if pirfenidone capsules can help people with pneumoconiosis, a lung disease caused by inhaling dust like coal or silica. About 272 adults with silicosis or coal worker's pneumoconiosis will receive either the drug or a placebo for 52 weeks. The main goal is to se…

This study tests a drug called Hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the drug three times daily for 28 days to see if it is safe. The goal is to manage the disease, not cure it, as patients must continue their usual antivir…

This study tests a new drug called F573 in people with liver injury or liver failure. The goal is to see if it is safe and how it affects the body. About 97 adults will take part, and half will get the drug while the other half gets a placebo. The study focuses on safety and does…

This study tests a drug called pirfenidone for people with lung damage caused by radiation therapy, with or without additional lung inflammation from immunotherapy. About 298 adults with grade 2 or 3 lung injury will receive either pirfenidone or a placebo for 24 weeks. The goal …

This study tests the safety of a drug called hydronidone in 200 adults with liver scarring (fibrosis) caused by chronic hepatitis B or fatty liver disease. Participants take three capsules three times a day for 28 days. The main goal is to track any side effects that occur during…

This study tests whether high doses of hydronidone capsules are safe for people with liver scarring (fibrosis) or cirrhosis caused by chronic hepatitis B. About 300 adults will take the drug three times daily for 28 days and be monitored for side effects. The goal is to see if th…

This study tests a single dose of hydroxynidone capsules in 56 people with mild to severe kidney problems and healthy volunteers. The goal is to see how the drug moves through the body and if it is safe. Results will help doctors decide the right dose for patients with kidney iss…

This early-stage study tests a new medicine called F230 in 136 healthy adults to see if it is safe and how the body processes it. The drug is designed to treat pulmonary hypertension, a serious lung condition. Researchers will also check if food changes how the drug works. No dir…